Axon Enterprise (AXON) Rises +28% Over 30 Days on Analyst Upgrades and Strong Bookings Momentum
Key Takeaways
- Axon Enterprise (AXON) surged approximately 28% over the last 30 days, climbing from a June 17 close of $423.01 to $541.75 as of July 16, 2026.
- A Needham price target upgrade from $600 to $750 on July 6, driven by strong bookings checks and a major Los Angeles Police Department contract expansion, served as the primary catalyst for the rally.
- First-quarter 2026 results, reported in early May, beat expectations with EPS of $1.61 on revenue of $807.35 million — up 33.7% year-over-year — setting a bullish foundation that carried into the following weeks.
- Massive institutional accumulation continued, with Baillie Gifford, Wellington Management, and Sands Capital all significantly increasing their positions during recent quarters.
- The stock's rally occurred against a backdrop of broader market weakness, highlighting company-specific strength tied to a $14.3 billion contracted bookings backlog and surging Dedrone counter-drone revenue.
Axon Enterprise (AXON) Company Overview and Market Position
Axon Enterprise, Inc. develops integrated hardware and software solutions for public safety and law enforcement agencies worldwide. The company's product ecosystem spans conducted energy weapons (TASER devices), body-worn cameras, in-car camera systems, and a cloud-based digital evidence management platform known as Axon Evidence. Axon also offers AI-powered tools such as Draft One for automated report writing, along with records management and real-time situational awareness software. Through its Dedrone acquisition, Axon has expanded into counter-drone technology, a segment that has seen explosive growth driven by security needs at large-scale events. With a contracted bookings backlog of $14.3 billion and approximately 79% institutional ownership, AXON occupies a dominant position at the intersection of public safety technology and recurring software revenue.
AXON Stock Price Performance: Last 30 Days vs. Quarter
Over the 30-day period ending July 16, 2026, AXON shares climbed from $423.01 to $541.75 — a gain of roughly 28%. The move was not linear. The stock bottomed around $410 on June 22 before beginning a powerful ascent that carried it to an intra-quarter high of $665.07 on July 7. A subsequent pullback to the mid-$540s reflects normal profit-taking after a sharp run rather than any deterioration in fundamentals.
Zooming out to the trailing quarter, the performance is even more dramatic. AXON traded as low as $339.01 in early April 2026 — its 52-week low — before staging a multi-month recovery. From that April trough through the mid-July close of $541.75, the stock rebounded approximately 60%. The turnaround was fueled by the May 6 earnings beat, a steady drumbeat of analyst upgrades and price target increases, and mounting evidence that Axon's bookings pipeline is accelerating across both its core law enforcement business and newer verticals like counter-drone defense.
What Drove AXON Stock Price in the Last 30 Days
The single most powerful catalyst during this window was Needham & Company's July 6 research note, which raised Axon's price target from $600 to $750 and reiterated a Buy rating. Needham's proprietary industry checks pointed to robust second- and third-quarter bookings momentum, anchored by two specific developments: the Los Angeles Police Department more than doubling its annual spending with Axon to $22 million, and a surge in Dedrone counter-drone opportunities linked to security deployments for the FIFA World Cup. Needham projected full-year 2026 bookings growth of approximately 34% to 35%, framing Axon's premium valuation as sustainable.
Additional analyst support reinforced the move. JPMorgan Chase raised its target to $755 with an Overweight rating in early May. TD Cowen named Axon its top pick for 2026. Citizens Jmp reiterated a Market Outperform rating with a $700 target in late June. Piper Sandler lifted its target from $674 to $724. By mid-July, fifteen analysts rated the stock Buy, three rated it Hold, and the consensus price target stood at approximately $725 — implying meaningful upside even after the rally.
On the institutional front, SEC filings revealed significant accumulation: Baillie Gifford increased its stake by nearly 1,200% during the fourth quarter, Wellington Management Group raised its position by 327%, and Sands Capital Management added 11.6%. Overall institutional ownership reached 79.08%. While insider selling did occur — including CEO Patrick Smith's sale of 10,000 shares at $643.79 under a pre-arranged 10b5-1 plan — these transactions were viewed as routine portfolio management rather than a signal of deteriorating confidence.
What Drove AXON Stock Performance Over the Last Quarter
Axon's quarterly surge from its April lows reflects a broader reassessment of the company's growth trajectory. The first-quarter 2026 earnings report on May 6 served as the inflection point: revenue of $807.35 million exceeded the $778.90 million consensus and represented 33.7% year-over-year growth, while EPS of $1.61 edged past the $1.60 estimate. More importantly, management disclosed a contracted bookings backlog of $14.3 billion — a figure that dramatically expanded the addressable revenue visibility for the company.
Dedrone, acquired by Axon, emerged as a breakout growth driver during the quarter, with counter-drone revenue reportedly surging roughly 300%. This positioned Axon to capture spending tied to high-profile security events including the FIFA World Cup. Meanwhile, new product cycles — TASER 10, Axon Body 4, and the AI-powered Draft One tool — continued to raise average deal values and deepen customer lock-in across law enforcement agencies. The combination of SaaS-like recurring revenue, accelerating hardware adoption, and a massive future contracted pipeline reshaped the investment narrative from a premium valuation concern to a growth-at-scale conviction story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Enhancing Research with Tickeron Tools
When reviewing fast-moving names like AXON, I sometimes reference Tickeron's Trending AI Robots page for additional context on algorithmic strategies. While Tickeron hosts hundreds of AI-powered trading bots covering thousands of tickers across multiple exchanges, only the top-performing and most contextually relevant bots appear in this featured section. Each bot operates on a distinct combination of strategy, timeframe, and performance metrics — ranging from short-term momentum plays to longer-duration trend-following models. The curated selection allows users to observe which automated approaches are currently generating the strongest risk-adjusted returns. Browsing the Trending AI Robots page can help traders identify patterns and strategies that align with their own market outlook.
AXON Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most critical near-term event is Axon's second-quarter 2026 earnings report, expected in early August. The Zacks Consensus Estimate calls for EPS of $1.89 on revenue of $868.35 million, and investors will scrutinize whether the bookings momentum highlighted by Needham translates into reported numbers. Any update to full-year guidance — particularly around the Dedrone segment and international contract expansion — could materially move the stock. Macroeconomic factors, including interest rate policy and government budget allocations for public safety technology, remain important backdrop variables. Competitive dynamics in AI-driven law enforcement software and the pace of TASER 10 and Axon Body 4 adoption cycles will also shape the investment narrative through the remainder of 2026. While the stock's forward P/E ratio above 70 reflects elevated growth expectations, the $14.3 billion backlog provides a tangible buffer that many high-growth peers lack. From what I see, this backlog remains a key differentiator worth monitoring closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXON sees MACD Histogram crosses below signal line
AXON saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 39 instances where the indicator turned negative. In of the 39 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AXON moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
AXON moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 373 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 260 cases where AXON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (9.779). P/E Ratio (205.758) is within average values for comparable stocks, (89.680). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.013). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (14.124) is also within normal values, averaging (31.039).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement